Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: Is it possible to identify patients likely to have good treatment outcomes?

Japanese Journal of Clinical Oncology

Volumn 32, Issue 11, 2002, Pages 466-471

  Kurokawa, Kohei ^a   Ito, Kazuto ^a   Suzuki, Kazuhiro ^a   Ono, Yoshihiro ^a   Yamamoto, Takumi ^a   Akimoto, Tetsuo ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Hormone refractory; Prostate cancer; PSA kinetics; Salvage radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MALE; PATIENT IDENTIFICATION; PREDICTION; PROSTATE CANCER; RETROSPECTIVE STUDY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; BLOOD; COMPUTER ASSISTED RADIOTHERAPY; MORTALITY; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0036832501     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyf096     Document Type: Article

References (22)

1. Kurokawa K, Fukabori Y, Ito K, Suzuki K, Nakata S, Suzuki K, et al. Clinical characteristics of prostate cancer in Gunma Prefecture. Int J Androl 2000;23 (Suppl 2):40-2.
2. Pound CR, Partin AW, Eisenberger M, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999;281:1591-7.
3. Partin AW, Pound CR, Pearson JD, Clemens JQ, Landis PK, Epstein J, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-59.
4. Nakata S, Takahashi H, Takezawa Y, Kobayashi M, Matsumoto K, Kosaku N, et al. PSA doubling time in prostate cancer relapsed after endocrine therapy. Nippon Hinyoukika Gakkai Zasshi 2000;91:584-8 (in Japanese).
5. Kawakami S, Kawai T, Yonese J, Yamauchi T, Ishibashi K, Ueda T. Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer. Nippon Hinyoukika Gakkai Zasshi 1993;84:1681-4 (in Japanese).
6. Furuya Y, Akakura K, Akimoto S, Ichikawa T, Ito H. Radiotherapy for local progression in patients with hormone-refractory prostate cancer. Int J Urol 1999;6:187-91.
7. Zeitman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to T2 adenocarcinoma of the prostate: New insights into outcome from repeat biopsy and prostate specific antigen follow up. J Urol 1994;152:1806-12.
8. 125I prostate implantation. Int J Radiat Oncol Biol Phys 1993;27 (Suppl 1): 228.
9. Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Fraizer RC, Martinez AA. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 1999;86:1557-66.
10. Aref I, Eapen O, Cross P. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiat Oncol 1998;48:203-7.
11. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-42.
12. Foster LS, Jajodia P, Fournier G Jr, Shinohara K, Carrol P, Narayan P. The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol 1993;149:1024-8.
13. Kapoor DA, Wasserman NF, Zhang G, Reddy PK. Value of transrectal ultrasound in identifying local disease after radical prostatectomy. Urology 1993;41:594-7.
14. Fowler JE Jr, Brooks J, Pandey P, Seaver LE. Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol 1995;153:1011-4.
15. Ornstein DK, Oh J, Herschman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 1998;25:591-601.
16. Cher ML, Bianco FJ Jr, Lam JS, Davis L, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevation after radical prostatectomy. J Urol 1998;160: 1387-91.
17. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, et al. Radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83:739-47.
18. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-50.
19. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10.
20. D'amico AV. Analysis of the clinical utility of the use of salvage brachytherapy in patients who have a rising PSA after definitive external beam radiation therapy. Urology 1999;54:201-3.
21. Izawa JI, Perrotte P, Greene GF, Scott S, Levy L, McGuire E, et al. Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol 2001;165:867-70.
22. Amling C, Bergstralh EJ, Blute ML, Slezak JM, Zinke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001;165:1146-51.